Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain

Area of Science:

• Immunology
• Mycology
• Infectious Diseases

Background:

• Cryptococcus neoformans causes pulmonary infections.
• Cell-mediated immunity (CMI) is crucial for controlling fungal infections.
• Understanding Th1/Th2 immune balance is key to effective anti-fungal strategies.

Purpose of the Study:

• To evaluate CMI responses in mice infected with C. neoformans engineered to produce gamma interferon (IFN-gamma).
• To assess the protective efficacy of this engineered strain against subsequent cryptococcal challenges.
• To investigate the impact of IFN-gamma production on pulmonary cytokine profiles and immune cell recruitment.

Main Methods:

• Pulmonary infection model in mice using wild-type and IFN-gamma-producing C. neoformans strains.
• Analysis of pulmonary cytokine and chemokine expression.
• Quantification of fungal burden, leukocyte, and T-lymphocyte populations in the lungs.

Main Results:

• Mice infected with the IFN-gamma-producing strain resolved primary infections and showed 100% protection against secondary challenge.
• Significantly higher Th1-type/proinflammatory cytokines and chemokines, and lower Th2-type cytokines were observed in the lungs.
• Lower fungal burden and increased leukocyte/T-lymphocyte recruitment were associated with IFN-gamma production.

Conclusions:

• Pulmonary infection with IFN-gamma-producing C. neoformans stimulates protective Th1-type CMI responses.
• Engineered fungi producing cytokines represent a novel method for studying immune responses and developing vaccine strategies.
• This approach demonstrates potential for enhancing host immunity against pulmonary cryptococcal infections.